![Bernard Pau](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Bernard Pau founded Biodol Therapeutics SAS in 2015.
Dr. Pau also currently works at Phost’in SAS, as Chairman & Chief Operating Officer from 2020.
Postes actifs de Bernard Pau
Sociétés | Poste | Début |
---|---|---|
Phost’in SAS
![]() Phost’in SAS Pharmaceuticals: MajorHealth Technology Phost’In SAS operates as a biotechnology company, which engages in the discovery and development of N-glycosylation inhibitors. Its potent anti-cancer new chemical entities specifically targeting abnormal pathogenic glycosylation mechanisms. The company was founded by Karine Chorro and Ludovic Clarion in December 2014 and is headquartered in France. | Président | 17/06/2020 |
Anciens postes connus de Bernard Pau
Sociétés | Poste | Fin |
---|---|---|
Biodol Therapeutics SAS
![]() Biodol Therapeutics SAS BiotechnologyHealth Technology Biodol Therapeutics SAS engages in the development of compounds for the treatment of chronic pain. It specializes in parallel small-molecule FLT3 inhibitors. The company was founded by Fabien Granier, Pierre Sokoloff and Bernard Pau in 2015 and is headquartered in Clapiers, France. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Phost’in SAS
![]() Phost’in SAS Pharmaceuticals: MajorHealth Technology Phost’In SAS operates as a biotechnology company, which engages in the discovery and development of N-glycosylation inhibitors. Its potent anti-cancer new chemical entities specifically targeting abnormal pathogenic glycosylation mechanisms. The company was founded by Karine Chorro and Ludovic Clarion in December 2014 and is headquartered in France. | Health Technology |
Biodol Therapeutics SAS
![]() Biodol Therapeutics SAS BiotechnologyHealth Technology Biodol Therapeutics SAS engages in the development of compounds for the treatment of chronic pain. It specializes in parallel small-molecule FLT3 inhibitors. The company was founded by Fabien Granier, Pierre Sokoloff and Bernard Pau in 2015 and is headquartered in Clapiers, France. | Health Technology |